Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"enGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"enGene Gets FDA Clearance of IND Application for EG-70","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"enGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"enGene Announces Positive Preliminary Phase 1\/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"enGene","sponsor":"Forbion Growth","pharmaFlowCategory":"D","amount":"$115.0 million","upfrontCash":"Undisclosed","newsHeadline":"enGene, Inc. and Forbion European Acquisition Corp. (\u201cFEAC\u201d, Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"enGene","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"enGene Announces Oversubscribed $200 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"enGene","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"enGene Announces Expanded $50 Million Debt Facility with Hercules Capital","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by enGene

    Menu

    enGene

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              enGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              enGene Announces Oversubscribed $200 Million Private Placement Financing

              Details:

              The net proceeds will be used for the clinical development of EG-70 (detalimogene voraplasmid) for the treatment of non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin treatment.

              Lead Product(s): Detalimogene Voraplasmid

              Therapeutic Area: Oncology Product Name: EG-70

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Adage Capital Partners

              Deal Size: $200.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement February 14, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              enGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

              Details:

              The financing will be used for the advancement of EG-70 (detalimogene voraplasmid) as an entirely new genetic medicine approach to treat BCG-unresponsive non-muscle invasive bladder cancer.

              Lead Product(s): Detalimogene Voraplasmid

              Therapeutic Area: Oncology Product Name: EG-70

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Hercules Capital

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing December 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              enGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              enGene, Inc. and Forbion European Acquisition Corp. (“FEAC”, Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Develop...

              Details:

              The net proceeds are expected to be used to fund the clinical development of intravesical EG-70 (detalimogene voraplasmid), a monotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive NMIBC with CIS.

              Lead Product(s): Detalimogene Voraplasmid

              Therapeutic Area: Oncology Product Name: EG-70

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Forbion Growth

              Deal Size: $115.0 million Upfront Cash: Undisclosed

              Deal Type: Financing May 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              enGene

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

              Details:

              EG-70 is a novel non-viral gene therapy encoding two RIG-I agonists to stimulate the innate immune system, and IL-12 to stimulate the adaptive immune system. It is being investigated for NMIBC in patients with carcinoma in situ that are BCG-unresponsive.

              Lead Product(s): EG-70

              Therapeutic Area: Oncology Product Name: EG-70

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              enGene

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              enGene Gets FDA Clearance of IND Application for EG-70

              Details:

              The study design consists of an open label dose escalation Phase 1 study to evaluate the safety and tolerability of EG-70 and to determine the recommended Phase 2 dose, followed by a Phase 2 portion to evaluate efficacy and safety.

              Lead Product(s): EG-70

              Therapeutic Area: Oncology Product Name: EG-70

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY